Tulip Interfaces

Tulip Interfaces is a frontline operations platform vendor founded in 2012 out of MIT, headquartered in Somerville, Massachusetts. The company delivers a no-code manufacturing app platform enabling manufacturers to increase productivity, quality, and efficiency through composable digital solutions. Founded by Natan Linder and Rony Kubat, Tulip has raised $153M–$171M in total funding, including a $100M Series C round in August 2021 led by Insight Partners.

The flagship platform lets operations teams build, deploy, and modify manufacturing applications through visual drag-and-drop tools without programming expertise. In January 2025, Tulip introduced Composable MES for Pharma, an offering targeting pharmaceutical and life sciences manufacturers with pre-built validated apps for electronic batch records, logbooks, weigh & dispense, sampling, and packaging operations, deployable in as little as 90 days.

Tulip serves manufacturers across industries including pharmaceuticals, medical devices, automotive, aerospace, consumer goods, and electronics, with notable pharma customers including GSK and Johnson & Johnson. The company operates offices across 4 continents (North America, Europe, and Asia) with 330+ employees as of 2025.

Investors include Insight Partners, New Enterprise Associates (NEA), Pitango, Breyer Capital, and Stanley Ventures.

Tulip is a multi-industry frontline operations platform vendor that introduced dedicated pharmaceutical capabilities in January 2025 with its Composable MES for Pharma offering. It is not pharma-exclusive. The company offers pre-built validated applications for electronic batch records, weigh & dispense, sampling, packaging, equipment logbooks, line clearance, and operator training compliance, designed for regulated pharmaceutical manufacturing environments.

Notable publicly disclosed pharma customers include GlaxoSmithKline (GSK), represented by a Pharma Supply Chain Tech Digital Innovation Lead at Tulip's Life Sciences Day event, and Johnson & Johnson, represented by a Manufacturing for the Future Product Line Leader at the same event. Tulip reports pharmaceutical customers achieving a 75% reduction in time spent reviewing detailed logbooks and 30% faster processes with digital guidance and audit trails.

Pharma-specific features include a Computer System Assurance (CSA)-based validation approach, 21 CFR Part 11 and Annex 11 compliance out of the box, GMP adherence with user access controls, and 90-day implementation timelines.

Tulip Interfaces has raised $153M–$171M in total funding across 5 rounds from 17 investors. The company's largest and most recent funding round was a $100M Series C in August 2021 led by Insight Partners (New York), with participation from New Enterprise Associates (NEA), its most recent investor.

Investors include Insight Partners (lead, Series C), New Enterprise Associates (NEA), Pitango, Breyer Capital, Plug and Play Tech Center, and Stanley Ventures.

Revenue is undisclosed; Tulip is a private company. The company continued active hiring in 2025, with new employees joining in September. No acquisitions or M&A activity are disclosed.

Tulip's product portfolio centers on the Tulip Frontline Operations Platform, a no-code app-building system enabling manufacturers to create interactive applications through drag-and-drop functionality without programming. The platform integrates four core capabilities: App Creation (visual no-code editor), Data Analytics (real-time AI-powered insights), Integrations (native connectivity to devices and enterprise systems), and Edge Devices (machine and sensor connectivity).

Composable MES for Pharma, announced January 2025, is the company's pharma-specific product line, with pre-built validated applications deployable in 90 days: Electronic Batch Records with real-time deviation alerts and quality checks; Weigh & Dispense automation for dosage calculations; Equipment Logbooks for automated data collection; Line Clearance documentation; and Operator Training compliance management. These solutions support validation requirements using Computer System Assurance (CSA) guidance.

AI capabilities include automated PDF-to-app conversion, text-prompt-to-dashboard generation, and ML-powered analytics. Multi-language support covers 28 languages via AI translation. The platform supports deployment across mobile devices, tablets, desktop workstations, Android/Windows headsets, and edge devices. Integration capabilities include a library of edge drivers and connectors, an Open API for customization, and real-time data synchronization with ERP, MES, and QMS systems. The modular architecture lets customers implement targeted solutions, such as only electronic batch records or weigh & dispense, instead of adopting the full MES suite.

Tulip has technology partnerships with OEM and automation ecosystem partners referenced on its website; specific partners are not named. In January 2025, Tulip announced a partnership with Sequence to develop digital manufacturing solutions eliminating paper-based records.

Tulip is delivered as SaaS; the hosting provider is undisclosed (AWS, Azure, and Google Cloud are not named). An Open API allows system integrator and consulting partners to build custom implementations. Integration capabilities connect to ERP platforms; no partnership with SAP, Oracle, or other ERP vendors is disclosed.

Tulip hosts Life Sciences Day, a pharma-focused event that has featured speakers from GSK and Johnson & Johnson. The company originated at MIT. Implementation is delivered directly by Tulip; no channel partner network is disclosed.

Tulip provides professional services for implementation, with rapid deployment timelines (90 days for Composable MES for Pharma). The no-code platform design reduces dependency on extensive professional services, since operations teams can build and modify applications directly; Tulip also offers implementation support for initial deployment and validation assistance for pharmaceutical environments.

Reviewers describe Tulip's support team as "friendly and knowledgeable," providing "prompt and effective solutions to issues" (Verified reviewer, G2). Support availability details — 24/7 coverage, regional support centers, multilingual support, and SLA commitments — are undisclosed on the website.

Training resources include platform documentation, product tours, and webinars. The company hosts customer events such as Life Sciences Day for pharmaceutical manufacturers. Certification programs for platform expertise are undisclosed. A user community or formal forum is undisclosed; the company maintains social media channels (LinkedIn, YouTube) for customer engagement.

Tulip was founded by MIT researchers Natan Linder and Rony Kubat. It has raised $153M–$171M from investors including Insight Partners and NEA, and named pharma customers include GlaxoSmithKline and Johnson & Johnson. No ISO 9001, ISO 27001, or SOC 2 certification is disclosed.

Tulip has a presence on Gartner Peer Insights for the Global Industrial IoT Platforms market; specific ratings and Magic Quadrant placement are undisclosed. G2 lists 35 reviews of Tulip citing ease of use, customization capabilities, and customer support; a numerical rating is undisclosed.

Executive team bios beyond the founders are undisclosed on the website. The company publishes blog content on manufacturing digital transformation, pharmaceutical MES modernization, and electronic batch records. Tulip hosts Life Sciences Day, with GSK and Johnson & Johnson among past participants.

Tulip's website (tulip.co) includes product information, industry-specific solutions pages (pharma manufacturing, medical devices), customer case studies, and educational resources including blog articles and webinars. The website offers a request-a-demo function and product tours. Content includes detailed technical documentation and material on manufacturing digital transformation topics.

A LinkedIn company page (18,550 followers) and a YouTube channel are linked in the website footer. 2025 announcements include the Composable MES for Pharma launch (January 2025) and the Sequence partnership. Press releases accompany major product launches and funding rounds.

Tulip markets itself around "Composable Operations" and "human-centric AI." The company positions itself around no-code accessibility, rapid deployment, and multi-industry applicability. Tulip's marketing materials describe the platform as the "industry's leading frontline operations platform."